Skip to main content

Dr. David W. Victor III, M.D.

Hepatology (Transplant Hepatology Physician)

  • Medicare participating

At a glance

Years since graduation
21
In the NPI registry since
2007
Medicare patients seen, 2024
475

Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Medical school: University of Kentucky College of Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Transplant Hepatology Physician primary
    TX license P7593 (first issued 2013; active)
  • Gastroenterology Physician
    MD license D0071978 · TX license P7593 (first issued 2013; active)
  • Hepatology Physician
    TX license P7593 (first issued 2013; active)
  • Internal Medicine Physician
    LA license 201516

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hepatology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
475
Services billed
1,166
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes459268
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes31699
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes8343
New patient office or other outpatient visit, 45-59 minutes4545
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes4544
Established patient office or other outpatient visit, 40-54 minutes3128
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope1716
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes1313
Established patient office or other outpatient visit, 10-19 minutes1211
New patient office or other outpatient visit, 60-74 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 17 companies reported 114 payments worth $105,729 in total to this clinician.

By company
Madrigal Pharmaceuticals$47,432
Ipsen Biopharmaceuticals, Inc$21,782
Intercept Pharmaceuticals, Inc.$17,463
Gilead Sciences, Inc.$12,182
Novo Nordisk Inc$4,064
Novo Nordisk As$1,965
Janssen Biotech, Inc.$269
AbbVie Inc.$168
By type
Compensation for services other than consulting (speaking, faculty)$66,879
Consulting Fee$23,685
Speaking at a medical education program$6,480
Food and Beverage$4,425
Travel and Lodging$4,259

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 8, 2025Ipsen Biopharmaceuticals, Inc
Feb 8, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$8,836
Sep 2, 2025Madrigal Pharmaceuticals
Sep 2, 2025
Consulting Fee
REZDIFFRA · LIVER DISEASE
$7,050
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Consulting Fee
OCALIVA · Hepatology / Gastroenterology
$5,400
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$5,288
Sep 4, 2025Ipsen Biopharmaceuticals, Inc
Sep 4, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$5,049
Oct 15, 2025Madrigal Pharmaceuticals
Oct 15, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Jul 18, 2025Intercept Pharmaceuticals, Inc.
Jul 18, 2025
Consulting Fee
OCALIVA · Hepatology / Gastroenterology
$4,320
Jan 27, 2025Madrigal Pharmaceuticals
Jan 27, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jul 29, 2025Madrigal Pharmaceuticals
Jul 29, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Aug 7, 2025Madrigal Pharmaceuticals
Aug 7, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
All 43 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 9, 2025Gilead Sciences, Inc.
Dec 9, 2025
Compensation for services other than consulting (speaking, faculty)
Livdelzi · INFLAM
Company’s description;4269551;AHM;10161673
$3,030
Dec 4, 2025Madrigal Pharmaceuticals
Dec 4, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Nov 11, 2025Gilead Sciences, Inc.
Nov 11, 2025
Compensation for services other than consulting (speaking, faculty)
Epclusa · HCV
Company’s description;4258154;AHM;10161673
$3,790
Oct 15, 2025Madrigal Pharmaceuticals
Oct 15, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$4,935
Oct 15, 2025Madrigal Pharmaceuticals
Oct 15, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to BRYAN, TX · in-kind
$1,008
Oct 10, 2025Ipsen Biopharmaceuticals, Inc
Oct 10, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$1,836
Sep 4, 2025Ipsen Biopharmaceuticals, Inc
Sep 4, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$5,049
Sep 2, 2025Madrigal Pharmaceuticals
Sep 2, 2025
Consulting Fee
REZDIFFRA · LIVER DISEASE
$7,050
Aug 25, 2025Ipsen Biopharmaceuticals, Inc
Aug 25, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$1,836
Aug 21, 2025Madrigal Pharmaceuticals
Aug 21, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind
$391
Aug 21, 2025Madrigal Pharmaceuticals
Aug 21, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind
$250
Aug 21, 2025Madrigal Pharmaceuticals
Aug 21, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL · in-kind
$221
Aug 21, 2025Madrigal Pharmaceuticals
Aug 21, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to CHICAGO, IL
$47.00
Aug 7, 2025Madrigal Pharmaceuticals
Aug 7, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jul 29, 2025Madrigal Pharmaceuticals
Jul 29, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$5,288
Jul 18, 2025Intercept Pharmaceuticals, Inc.
Jul 18, 2025
Consulting Fee
OCALIVA · Hepatology / Gastroenterology
$4,320
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind
$317
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind
$244
Jul 18, 2025Madrigal Pharmaceuticals
Jul 18, 2025
Travel and Lodging
REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind
$232
Jul 17, 2025Madrigal Pharmaceuticals
Jul 17, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$1,763
Jul 14, 2025Intercept Pharmaceuticals, Inc.
Jul 14, 2025
Speaking at a medical education program
OCALIVA · Hepatology / Gastroenterology
$3,240
Jun 24, 2025Intercept Pharmaceuticals, Inc.
Jun 24, 2025
Speaking at a medical education program
OCALIVA · Hepatology / Gastroenterology
$3,240
Jun 4, 2025Gilead Sciences, Inc.
Jun 4, 2025
Consulting Fee
Livdelzi · INFLAM
Company’s description;4147927;VEM US;10161673
$1,020
May 28, 2025Gilead Sciences, Inc.
May 28, 2025
Compensation for services other than consulting (speaking, faculty)
Epclusa · HCV
Company’s description;4113537;AHM;10161673
$3,790
May 11, 2025Novo Nordisk As
May 11, 2025
Consulting Fee
Multiple Therapeutic Areas
$983
May 1, 2025Ipsen Biopharmaceuticals, Inc
May 1, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$2,754
Apr 28, 2025Novo Nordisk Inc
Apr 28, 2025
Consulting Fee
Multiple Therapeutic Areas
$1,638
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Consulting Fee
OCALIVA · Hepatology / Gastroenterology
$5,400
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL
$300
Mar 29, 2025Intercept Pharmaceuticals, Inc.
Mar 29, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$49.00
Mar 28, 2025Intercept Pharmaceuticals, Inc.
Mar 28, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$257
Mar 28, 2025Intercept Pharmaceuticals, Inc.
Mar 28, 2025
Travel and Lodging
OCALIVA · Hepatology / Gastroenterology · travel to Chicago, IL · in-kind
$204
Mar 24, 2025Madrigal Pharmaceuticals
Mar 24, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$1,763
Mar 13, 2025Novo Nordisk As
Mar 13, 2025
Consulting Fee
Multiple Therapeutic Areas
$983
Mar 12, 2025Madrigal Pharmaceuticals
Mar 12, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$2,820
Mar 11, 2025Madrigal Pharmaceuticals
Mar 11, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$1,763
Feb 17, 2025Novo Nordisk Inc
Feb 17, 2025
Consulting Fee
Multiple Therapeutic Areas
$2,293
Feb 8, 2025Ipsen Biopharmaceuticals, Inc
Feb 8, 2025
Compensation for services other than consulting (speaking, faculty)
IQIRVO · Rare Disease
$8,836
Feb 8, 2025Ipsen Biopharmaceuticals, Inc
Feb 8, 2025
Travel and Lodging
IQIRVO · Rare Disease · travel to Dallas, TX · in-kind
$441
Feb 8, 2025Ipsen Biopharmaceuticals, Inc
Feb 8, 2025
Travel and Lodging
IQIRVO · Rare Disease · travel to Dallas, TX · in-kind
$299
Jan 27, 2025Madrigal Pharmaceuticals
Jan 27, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$3,878
Jan 17, 2025Madrigal Pharmaceuticals
Jan 17, 2025
Compensation for services other than consulting (speaking, faculty)
REZDIFFRA · LIVER DISEASE
$2,115

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $98,367 in research payments for these studies, mostly to the institutions running them.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hepatology clinicians in Houston

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 14, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1508048919. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.